Study suggests a diabetes drug under investigation for both Parkinson’s and Alzheimer’s diseases acts by quieting microglia and shutting down the pathological activation of astrocytes.
After veru- and atabecestat, now a third β-secretase inhibitor, by Eli Lilly and AstraZeneca, is being pulled from ongoing Phase 3 trials of symptomatic Alzheimer’s disease.
Though the dipeptides interacted with many proteins in cell culture, they associated specifically with ribosomes in the human brain.
In mice, antisense oligonucleotides that splice out more than half of the Aβ peptide drive down its levels in the brain.
By prying open chromatin, neurofibrillary tau may expose dormant transposable elements for transcription.
Recent studies have identified rare loss-of-function variants that cause Alzheimer’s with nearly 100 percent penetrance. Now there are 17 more.
In 18-month data from a small trial, elenbecestat appeared well-tolerated, with no signs of liver toxicity. PET imaging indicated a drop in brain amyloid, while clinical endpoints trended toward a slowing of cognitive decline.
Outcomes emphasize big data, new technology, environmental and genetic risk in hopes of enabling precision medicine.
Big Data Was the Big Theme at Shortened NIH Summit 2018 Alzheimer’s Disease Research Summit ...
Making deeper inroads into Alzheimer’s systems biology, groups of genes co-expressed in the cortex associated with clinical and pathological traits of the disease, notably the slope of cognitive decline.
New data suggest that the proteasome takes the first stab at dissolving these protein conglomerates, with autophagy coming in later to mop up.
Contradicting current opinion, a randomized trial made people stronger but, if anything, left their mental function weaker. What gives?
Antisense oligonucleotides are raising hopes for tackling a wide range of brain disorders—is the enthusiasm warranted?
As RNA Therapies Come of Age, Efficacy Remains Weak At AAN, Sights Set on Antisense Therapies for Diseases of the Brain New Alzheimer’s and Parkinson’s Immunotherapy Data at AAN Will RNA molecules that bump up or tamp down gene expression live up to their ...
At AAN, the latest data from Phase 3 trials and open-label extensions of RNA-targeting therapies reveal a bit of benefit, but no cure.
No filters selected